TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
Helsinki, Finland – 11th October 2022: TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the first US patient has been dosed in its ovarian cancer trial (NCT05271318), using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indication.
